Timo joined mAbxience in March 2022 as Chief Scientific Officer and member of the Executive Team, overseeing the Research and Development, Process Improvement and Technology Transfer and Program Management teams within the mAbxience organization.
Timo is a senior biopharmaceutical development, regulatory and program management expert with a very diverse skillset and in-depth experience in evaluating and developing biosimilars and innovative biopharmaceuticals. Timo also brings years of hands-on experience in the biopharmaceutical CDMO* field to mAbxience.
In his most recent roles prior to joining mAbxience, Timo held several senior management positions and spearheaded the entire CMC R&D development organization (Alvotech) and worked for the last 1,5 years as a regulatory and development consultant for biopharmaceutical products of diverse nature, from cell and gene therapy products to innovative and biosimilar monoclonal antibodies and other complex proteins (PharmaLex/Biopharma Excellence).
Timo holds a PhD degree in biology from Imperial College London and a MSc degree in regulatory affairs for biopharmaceuticals.